Castle Biosciences (CSTL) Total Current Liabilities (2018 - 2026)

Castle Biosciences has reported Total Current Liabilities for 9 years, with the latest figure at $56.5 million in Q2 2026.

• Quarterly Total Current Liabilities rose 11.04% year-over-year to $56.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $56.5 million (up 11.04% YoY) and the FY2025 annual result came in at $68.7 million, up 39.04% from the prior year.
• Total Current Liabilities improved to $56.5 million in Q2 2026 per CSTL's latest filing, from $48.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $68.7 million in Q4 2025 and troughed at $27.5 million in Q2 2022.
• A 5-year average of $42.5 million and a median of $39.5 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 124.83% in 2022, then slipped 23.73% in 2023.
• Over 5 years, Total Current Liabilities stood at $36.1 million in 2022, then jumped by 31.94% to $47.7 million in 2023, then advanced by 3.62% to $49.4 million in 2024, then jumped by 39.04% to $68.7 million in 2025, then dropped by 17.72% to $56.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $56.5 million, $48.8 million, and $68.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.